NYU researchers have shown that the induction of NKG2D ligands contributes to the synergy of radiotherapy with an anti-CTLA-4 mAb. The findings could be used to identify patients most likely to respond to anti-CTLA-4 treatment and to help establish which radiation regimens would enhance the treatment.